文献速递前列腺癌

MUSegNet:微超声上临床显著性前列腺癌的自动检测

MUSegNet: Automated detection of clinically significant prostate cancer on micro-ultrasound.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2026-09-22

本研究开发了基于nnUnet的MUSegNet,用于在微超声(microUS)上自动分割前列腺、移行区和临床显著性前列腺癌(csPCa)。MUSegNet在独立测试中检测csPCa的AUROC为0.85,显著优于手动标签训练的基线模型(0.73),并优于六位专家读者(0.78)。MUSegNet对后部病灶检测最佳(AUROC 0.94),并发现了33%的MRI不可见癌症。

要点

  • MUSegNet在微超声上自动检测csPCa的AUROC为0.85,优于基线模型和六位专家。
  • MUSegNet对后部病灶检测最佳(AUROC 0.94),对前部病灶也有一定效果(AUROC 0.72)。
  • MUSegNet在33%的csPCa病例中发现了MRI不可见的癌症。

核心结论

  • MUSegNet能可靠检测微超声上临床显著性前列腺癌的范围,有望改善活检靶向并减少读者间差异。

研究设计与样本

  • 研究使用nnUnet框架开发MUSegNet,训练数据包括53例手动标注的microUS检查(53例患者)、565例未标注microUS检查(106例患者)和2749例传统B型超声检查(2281例患者)。
  • 在来自两个机构的73例独立患者中评估MUSegNet,并与手动标签和六位专家读者直接比较。

主要发现

  • MUSegNet检测csPCa的AUROC为0.85,显著优于手动标签训练的基线模型(0.73,Delong p值<0.01),灵敏度为0.74 vs. 0.27,Dice相似系数为0.29 vs. 0.09(Wilcoxon p值<0.001)。
  • MUSegNet检测后部病灶的AUROC为0.94,灵敏度0.86,Dice 0.31;检测前部病灶的AUROC为0.72,灵敏度0.49,Dice 0.11。
  • MUSegNet在所有病灶上均优于六位人类读者(AUROC 0.85 vs. 0.78,灵敏度0.74 vs. 0.63)。
  • MUSegNet在33%的csPCa病例中发现了MRI不可见的癌症(三分之一)。

临床怎么用

  • MUSegNet可用于微超声检查中自动检测临床显著性前列腺癌,辅助活检靶向并减少读者间差异。

局限性

  • 需要在更大队列中进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Micro-ultrasound (microUS) is a non-inferior alternative to multi-parametric MRI for clinically significant prostate cancer (csPCa) diagnosis, yet cancer's subtle features result in missed cancers and large inter-reader variability. We seek to automate the detection of csPCa on microUS by developing the microUS Prostate Cancer Detection Network (MUSegNet). METHODS: Implemented using the well-established segmentation framework, nnUnet, MUSegNet automatically outlines the prostate, transitional zone, and csPCa. Our study explored strategies to train such segmentation models given reduced data, which is common with new imaging modalities such as microUS and/or when labeling data is tedious. MUSegNet was trained using three datasets: (1) 53 microUS exams manually labeled using MRI and pathology references (53 patients), (2) 565 unlabeled microUS exams (106 patients), and (3) 2749 conventional b-mode ultrasound exams (2281 patients). We evaluated MUSegNet in 73 independent patients from two institutions, against manual labels and in direct comparison with six expert readers. RESULTS: MUSegNet was significantly better at detecting csPCa than the baseline models trained using manual labels (area under the receiver operating characteristic curve - AUROC; 0.85 vs. 0.73, Delong p-value < 0.01, sensitivity: 0.74 vs. 0.27, dice similarity coefficient: 0.29 vs. 0.09, Wilcoxon p-value < 0.001). MUSegNet was better at detecting posterior vs. anterior lesions (AUROC: 0.94 vs. 0.72, sensitivity: 0.86 vs. 0.49, Dice: 0.31 vs. 0.11) and outperformed the six human readers for all lesions (AUROC: 0.85 vs. 0.78, sensitivity: 0.74 vs. 0.63). While evaluation in a larger cohort is needed, MUSegNet found csPCA in 33% of cases with csPCa and MRI invisible cancers (1 in 3). CONCLUSIONS: MUSegNet reliably detected the extent of clinically significant prostate cancer on micro-ultrasound exams, paving the way for improving cancer detection for biopsy targeting and reducing inter-reader variability. MUSegNet was best at capturing posterior cancers, with some benefit for the challenging anterior cancers.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Rusu M, Zhou SR, Zhang L, et al. MUSegNet: Automated detection of clinically significant prostate cancer on micro-ultrasound. Prostate Cancer Prostatic Dis. 2026. PMID: 42773205. doi:10.1038/s41391-026-01157-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。